BANK VONTOBEL/PUT/MODERNA/120/0.1/20.09.24 | Real-time Boerse Frankfurt Warrants 01:43:19 2024-07-11 pm EDT | ||
| 0.9 EUR | -13.46% |
|
| Current month | -7.96% | ||
| 1 month | +131.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 0.9 | -13.46% |
| 24-07-10 | 1.04 | -11.86% |
| 24-07-09 | 1.18 | 0.00% |
| 24-07-08 | 1.18 | +1.72% |
| 24-07-05 | 1.16 | -3.33% |
Real-time Boerse Frankfurt Warrants
Last update July 11, 2024 at 01:43 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VD5J0A |
| ISIN | DE000VD5J0A0 |
| Date issued | 2024-05-03 |
| Strike | 120 $ |
| Maturity | 2024-09-20 (71 Days) |
| Parity | 10 : 1 |
| Emission price | 1.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.31 € |
|---|---|
| Lowest since issue | 0.28 € |
| Spread | 0.02 € |
| Spread % | 2.11% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.4
USD
Average target price
145.9
USD
Spread / Average Target
+24.19%
- Stock Market
- Warrants
- Warrant
